Opiant Pharmaceuticals (NASDAQ: OPNT) and Mobileye N.V. (NYSE:MBLY) are both technology companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.

Institutional and Insider Ownership

57.1% of Mobileye N.V. shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Opiant Pharmaceuticals and Mobileye N.V.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Opiant Pharmaceuticals -17,271.58% -245.18% -110.10%
Mobileye N.V. 29.43% 17.78% 15.85%

Analyst Ratings

This is a summary of current ratings and target prices for Opiant Pharmaceuticals and Mobileye N.V., as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Opiant Pharmaceuticals 0 0 0 0 N/A
Mobileye N.V. 1 20 2 0 2.04

Mobileye N.V. has a consensus price target of $55.27, suggesting a potential downside of 12.02%. Given Mobileye N.V.’s higher possible upside, analysts plainly believe Mobileye N.V. is more favorable than Opiant Pharmaceuticals.

Earnings & Valuation

This table compares Opiant Pharmaceuticals and Mobileye N.V.’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Opiant Pharmaceuticals $14.97 million N/A $5.99 million N/A N/A
Mobileye N.V. $407.63 million 34.22 $138.64 million $0.50 125.64

Mobileye N.V. has higher revenue and earnings than Opiant Pharmaceuticals.

Summary

Mobileye N.V. beats Opiant Pharmaceuticals on 9 of the 9 factors compared between the two stocks.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.

About Mobileye N.V.

Mobileye N.V. is engaged in the development of computer vision and machine learning-based sensing, mapping and driving policy technology for advanced driver assistance systems and autonomous driving technologies. The Company operates through two segments: Original Equipment Manufacturing, which supplies the software algorithms and EyeQ chip, and After Market, which sells a complete system, which includes its software algorithms and EyeQ chip, as well as the camera and other necessary components. Its software algorithms and EyeQ chips perform detailed interpretations of the visual field in order to anticipate possible collisions with other vehicles, pedestrians, cyclists, animals, debris and other obstacles. Its products are able to detect roadway markings; identify and read traffic signs, directional signs and traffic lights; create a Roadbook of localized drivable paths and visual landmarks using its road experience management technology, and provide mapping for autonomous driving.

Receive News & Stock Ratings for Opiant Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.